At Fierce Pharma Week, one challenge surfaced across panels, client meetings, and hallway conversations: pharma marketers have more intelligence than ever, but struggle to coordinate it across teams, audiences, and the treatment journey.
“Healthcare solutions are fragmented,” said Stephanie Alexander, Group Account Director. “The opportunity is to connect data, platforms, and people before the race for innovation creates even more silos.”
Butler/Till Health experts heard these tensions across the conference. Together, they point to five contradictions shaping pharma marketing.
Contradiction 1: AI Is Table Stakes, But It’s Creating New Divides
Nearly every vendor at Fierce Pharma Week showcased an AI capability. Every platform offers it, and every brand is adopting it. AI adoption is no longer the differentiator.
The divide is between brands that can connect their AI capabilities and those that can’t. Three integrated systems outperform ten disconnected tools.
“What stood out wasn’t a lack of intelligence,” said Maggie Leathersich, Director of Strategic Partnerships. “It was a lack of connectivity. The next wave of competitive advantage won’t come from who has the most AI capabilities. It will come from who can orchestrate them across data, platforms, and stakeholders to create seamless experiences.”
Contradiction 2: DTC Creates Awareness, But HCP Readiness Determines Success
Patient awareness matters. Getting someone to ask their doctor about your drug is the DTC job.
But patient interest has limited value if the HCP isn’t ready to prescribe. Provider readiness and patient interest need to work together.
“The convergence of DTC and HCP marketing was the central theme throughout the conference,” said Kendree Thieringer, Group Account Director. “Creating patient awareness is only part of the equation. The bigger opportunity is ensuring those patients connect with healthcare providers who are ready to have the conversation and prescribe when appropriate.”
Most brands still run these strategies separately. More effective programs coordinate them so each reinforces the other.
Contradiction 3: Real-Time Data Is Everywhere, But Coordination Is the Barrier
Real-time behavioral signals, intent data, and prescribing information are available faster than ever.
Visibility is useless without flexibility. You need both the data and the ability to act on it.
“Technology isn’t the biggest barrier to omnichannel success anymore,” said Michael Deichmiller, Senior Vice President, Client Engagement. “Coordination is. The opportunity for marketers is to connect patient, provider, and behavioral signals in ways that create a more seamless journey from awareness to action.”
“The value of real-time intelligence isn’t in seeing signals faster,” said Rachel Smith, Director, Integrated Planning. “It’s in having the flexibility to act on them.”
Annual plans with fixed budgets, static creative, and rigid channel allocations eliminate that flexibility. Shorter planning cycles and more fluid investment allow strategies to evolve as signals change.
Contradiction 4: The Prescription Is the Goal, But It’s Only the Middle
Pharma marketing often optimizes toward the prescription as the primary goal.
But the patient journey continues after the prescription, when access barriers often begin.
“If the industry is moving toward measuring customer progression rather than channel performance, then the prescription should be viewed less as an endpoint and more as a transition point within a larger treatment journey,” said Karen Munoz, Associate Director of Integrated Planning.
After the Rx is written, patients may face prior authorization delays, formulary restrictions, and adherence barriers, while HCPs navigate documentation. Marketing support often ends just as these barriers emerge.
More effective programs extend support into those post-Rx moments and measure progression across the full treatment journey.
Contradiction 5: More Data, But Trust Matters More
Pharma marketers have access to more data sources than ever—platforms, integrations, proprietary systems everywhere. The assumption is that more data leads to better decisions.
In healthcare, volume alone doesn’t produce better decisions. Trust matters more.
“Trust will be the next battleground of AI in health,” said Gina Whelehan, Group Director, Strategic Partnerships. “As AI becomes more embedded in healthcare, the conversation is shifting from access to information to trust in information—and whether AI-enabled experiences are grounded in medically credible, clinically relevant sources.”
Regulatory fluency matters. Clinical judgment matters. Medical credibility is what separates winners as AI scales.
Ways to Win
Brands navigating these contradictions successfully start with the same priority: connected infrastructure.
“Pharma marketers winning now are building identity differently,” said Wendy Emerson, Senior Vice President of Marketing Science. “They’re creating a trusted intelligence layer—connecting data, technology, privacy, and outcomes into a system that learns continuously. That means faster planning, real confidence in decisions, and experiences that work for patients and providers.”
When data, technology, privacy, and outcomes align, teams adjust strategy, measurement, and execution as conditions demand. The goal is building a connected system that helps teams respond to these contradictions with greater speed and confidence.
Contributors:
- Stephanie Alexander, Group Account Director
- Michael Deichmiller, Senior Vice President, Client Engagement
- Wendy Emerson, Senior Vice President of Marketing Science
- Maggie Leathersich, Director of Strategic Partnerships
- Karen Munoz, Associate Director of Integrated Planning
- Rachel Smith, Director, Integrated Planning
- Kendree Thieringer, Group Account Director
- Gina Whelehan, Group Director, Strategic Partnerships
